Study: NCT04241185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg of IV (intravenous) pembrolizumab once every 6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional Radiotherapy (Bladder only)
Description: 64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Radiotherapy (Bladder only)
Description: 64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional Radiotherapy (Bladder and pelvic nodes)
Description: 64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Radiotherapy (Bladder and pelvic nodes)
Description: 64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy (Bladder only)
Description: 55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Hypofractionated Radiotherapy (Bladder only)
Description: 55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorouracil (5-FU)
Description: 5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Description: MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitomycin C (MMC)
Description: MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Pembrolizumab
Description: Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.